APPROACHES TO IDENTIFYING, MEASURING, AND AGGREGATING ELEMENTS OF VALUE
Open Access
- 1 October 2013
- journal article
- research article
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 29 (4), 360-364
- https://doi.org/10.1017/s0266462313000524
Abstract
Background: Two general alternative approaches, cost-effectiveness analysis and the therapeutic added value approach, link the pricing and approval of drugs to value. Value as assessed by payers is a function of: benefit less cost, willingness to pay for benefit, and how they handle uncertainty.Methods: This study uses international examples to explore the elements of value that can be included in the assessment of health technologies, approaches to scoring the elements of value and how they can be combined to make a decision.Results: A range of value elements, measures, and approaches to aggregation are identified across different HTA systems. We show that seemingly arbitrary differences in measurement and aggregation can lead to significantly different outcomes, and argue that the choice of values, measures, and decision-making processes should be informed by the societal values that underpin a health system.Conclusions: We identify three areas for further research to improve both health system and industry R&D decision making: (i) whether more consistency could be achieved across health systems on the elements of value that matter; (ii) the relative merits of discrete versus continuous measures of value; and (iii) how structured decision making (to aggregate the elements of value) could or should become.Keywords
This publication has 11 references indexed in Scilit:
- Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global ContextHealth Economics, 2013
- Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluationHealth Policy, 2013
- Operationalizing Value-Based Pricing of MedicinesPharmacoEconomics, 2012
- USING HEALTH TECHNOLOGY ASSESSMENT TO SUPPORT OPTIMAL USE OF TECHNOLOGIES IN CURRENT PRACTICE: THE CHALLENGE OF “DISINVESTMENT”International Journal of Technology Assessment in Health Care, 2012
- Real Option Value and Path Dependence in Oncology InnovationInternational Journal of the Economics of Business, 2011
- Is quantitative benefit–risk modelling of drugs desirable or possible?Drug Discovery Today: Technologies, 2011
- Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part IIValue in Health, 2010
- Severity of illness and priority setting in healthcare: A review of the literatureHealth Policy, 2009
- Characterizing Structural Uncertainty in Decision Analytic Models: A Review and Application of MethodsValue in Health, 2009
- OFT, VBP: QED?Health Economics, 2007